Outlook TherapeuticsOTLK -5.07%11 Days Payable is 6,416.59 as of Mar. 2026, which is 163% above its 10-year median of 2,442.43. GuruFocus rates OTLK with a GF Score™ of 11/100. The stock has 6 warning signs investors should review. Among 704 Biotechnology companies, Outlook Therapeutics ranks better than 91.05% on this metric.
The historical rank and industry rank for Outlook Therapeutics's Days Payable or its related term are showing as below:
OTLK'
s Days Payable Range Over the Past 10 Years
Min: 2341.67 Med: 2442.43 Max: 2442.43
Current: 2341.67
During the past 12 years, Outlook Therapeutics's highest Days Payable was 2442.43. The lowest was 2341.67. And the median was 2442.43.
OTLK's Days Payable is ranked better than 91.05% of 704
companies
in the Biotechnology industry
Industry Median: 113.56
vs OTLK: 2341.67
Outlook Therapeutics's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (6,416.59).
It may suggest that Outlook Therapeuticsdelayed paying its suppliers.
Outlook Therapeutics Days Payable Related Terms
Outlook Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Outlook Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Outlook Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Outlook Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Outlook Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Outlook Therapeutics's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Outlook Therapeutics (OTLK) has a Days Payable of 6,416.59 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Outlook Therapeutics and its competitors. This is 163% above median its historical median of 2,442.43. Over the past decade, Outlook Therapeutics' Days Payable has ranged from 2,341.67 to 2,442.43. According to the industry distribution chart, Outlook Therapeutics ranks #63 out of 704 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Outlook Therapeutics' Days Payable too high?
Outlook Therapeutics' current Days Payable of 6,416.59 is 163% above median its 10-year median of 2,442.43. Over the past 10 years, this metric has ranged from a low of 2,341.67 to a high of 2,442.43. The Biotechnology industry median Days Payable is 113.56. Outlook Therapeutics' value of 6,416.59 is 5550.4% above this industry median. Based on the distribution chart, Outlook Therapeutics ranks #63 out of 704 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Outlook Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' Days Payable compare to FULC and OBIO?
According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #63 out of 704 companies for Days Payable. This places Outlook Therapeutics in the top 9% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Outlook Therapeutics' value of 6,416.59 is 5550.4% above this benchmark. Historically, Outlook Therapeutics' own Days Payable has ranged from 2,341.67 to 2,442.43 over the past decade. While the company's 10-year median is 2,442.43 vs. the industry median of 113.56, Outlook Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Outlook Therapeutics's current Days Payable of 6,416.59 is 5550.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Outlook Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Outlook Therapeutics's current Days Payable is 6,416.59, which is 163% above median its own 10-year median of 2,442.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current Days Payable of 6,416.59. The current Days Payable is 6,416.59, which is 163% above median its 10-year median of 2,442.43 and 5550.4% above the Biotechnology industry median of 113.56. Outlook Therapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current Days Payable is 6,416.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
11GF Score
Get the complete analysis for OTLK
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLK has been successfully added to your 
